

Markvicka Taunia  
Form 3  
March 29, 2012

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â Markvicka Taunia

(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

03/21/2012

3. Issuer Name and Ticker or Trading Symbol  
Pacira Pharmaceuticals, Inc. [PCRX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

Director  10% Owner

Officer  Other

(give title below) (specify below)

Vice President, Commercial

C/O PACIRA  
PHARMACEUTICALS,  
INC.,Â 5 SYLVAN WAY,  
SUITE 100

(Street)

PARSIPPANY,Â NJÂ 07054

(City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative

5. Ownership Form of Derivative Security:

6. Nature of Indirect Beneficial Ownership (Instr. 5)

## Edgar Filing: Markvicka Taunia - Form 3

|                                      | Date Exercisable | Expiration Date | Title        | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) |   |
|--------------------------------------|------------------|-----------------|--------------|----------------------------|----------|---------------------------------------|---|
| Employee Stock Option (right to buy) | Â (1)            | 09/01/2020      | Common Stock | 21,385                     | \$ 1.61  | D                                     | Â |
| Employee Stock Option (right to buy) | Â (2)            | 09/01/2020      | Common Stock | 29,754                     | \$ 1.61  | D                                     | Â |
| Employee Stock Option (right to buy) | Â (3)            | 12/28/2020      | Common Stock | 18,349                     | \$ 5.49  | D                                     | Â |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                              |       |
|---|---------------|-----------|------------------------------|-------|
|   | Director      | 10% Owner | Officer                      | Other |
| Markvicka Taunia<br>C/O PACIRA PHARMACEUTICALS, INC.<br>5 SYLVAN WAY, SUITE 100<br>PARSIPPANY, NJ 07054 | Â             | Â         | Â Vice President, Commercial | Â     |

## Signatures

/s/ Taunia  
Markvicka

03/29/2012

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests as follows: 25% of the shares shall vest on the one-year anniversary of the Vesting Commencement Date of September 2, 2010; 1/36th of the shares shall vest over the three year period thereafter.
  - (2) The stock option vests as follows: 50% of the shares are vested upon the date of grant; 50% of the remaining shares shall vest in monthly installments over the next 24 months.
  - (3) The stock option vests as follows: 25% of the shares shall vest on the one-year anniversary of the Vesting Commencement Date of December 29, 2010; 1/36th of the shares shall vest over the three year period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.